Sling Therapeutics, Inc., a US-based biopharmaceutical company, announced on Wednesday that it has named Jeffrey Kent, MD, FACG, FACP as its new chief medical officer (CMO), effective immediately.

In the new role, Dr Kent will head medical, clinical, and regulatory functions to support the global Phase 2b LIDS clinical trial assessing the safety, pharmacokinetics, and efficacy of linsitinib, a small molecule insulin-like growth factor I receptor (IGF-1R) inhibitor, to treat thyroid eye disease (TED).

Dr Kent has more than two decades of life sciences experience in clinical development, medical affairs and medical/commercial strategy. He has held the position of executive vice president, medical Affairs and Outcomes Research at Horizon Therapeutics, executive medical director at Astellas Pharma, global project head for HUMIRA at Abbott Laboratories and medical director at Searle Pharmaceuticals.